Algert Global LLC Alkermes Plc. Transaction History

Algert Global LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.21 - $27.24 $375,793 - $441,042	16,191 New	16,191 $390,000
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $2.74 Million - $3.36 Million	-117,282 Reduced 43.67%	151,261 $4.2 Million
Q3 2023 Nov 13, 2023	BUY	$27.17 - $31.97 $1.7 Million - $2 Million	62,674 Added 30.44%	268,543 $7.52 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $288,217 - $342,017	10,170 Added 5.2%	205,869 $6.44 Million
Q1 2023 May 12, 2023	BUY	$25.31 - $29.02 $475,802 - $545,546	18,799 Added 10.63%	195,699 $5.52 Million
Q4 2022 Feb 13, 2023	BUY	$21.94 - $26.24 $166,436 - $199,056	7,586 Added 4.48%	176,900 $4.62 Million
Q3 2022 Nov 15, 2022	BUY	$22.0 - $31.87 $1.54 Million - $2.23 Million	70,008 Added 70.5%	169,314 $3.78 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $1.15 Million - $1.33 Million	43,702 Added 78.6%	99,306 $2.96 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $1.28 Million - $1.56 Million	55,604 New	55,604 $1.46 Million
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $379,503 - $567,046	-17,676 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $413,088 - $567,929	17,676 New	17,676 $545,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.